Swipe om te navigeren naar een ander artikel
This work was presented at the ESC 2010 Congress (28 August to 1 September 2010, Stockholm), as oral abstract No. 3562.
This work was supported by Pfizer Limited.
The statin authorisation form implemented in the Netherlands in January 2009 has led to significant switching of patients from atorvastatin to generic simvastatin, but often to less than equipotent doses. We sought to assess the potential consequences of this.
A modelling analysis was undertaken using data from a pharmacy database covering the majority of drug prescriptions in the Netherlands. Recent meta-analyses provided data on the dose-specific, lipid-modifying potencies of atorvastatin and simvastatin, and the relationship between reduction in low-density lipoprotein cholesterol (LDL-C) achieved by statin therapy and relative reduction in risk of cardiovascular disease (CVD).
In the first quarter of 2009, 33.7%, 47.2% and 19.1% of Dutch patients initially on atorvastatin were switched to less potent, equipotent and more potent doses of simvastatin, respectively. The net effect was estimated to be a 6.8% increase in LDL-C. Assuming a pre-switch LDL-C of 2 mmol/L, the predicted relative increases (95%CI) in the risks of all-cause mortality and major cardiovascular events were 1.7% (0.9%–2.6%) and 2.8% (1.6%–4.1%), respectively.
In the Netherlands, policy-driven switching from atorvastatin to generic simvastatin led overall to less potent doses being used, with possible significant clinical implications.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28:2375–414. PubMedCrossRef
National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Technology appraisal 94. 2008. Available at: http://www.nice.org.uk/nicemedia/live/11564/33151/33151.pdf
Kwaliteitsinstituut voor de gezondheidszorg CBO en Nederlands Huisartsen Genootschap Multidisciplinaire richtijn Cardiovasculair risicomanagement. (In Dutch.) Utrecht, 2006.
College voor Zorgverzekeringen CVZ, Pakketadvies 2008. (In Dutch.) Diemen, 2008.
Stichting Farmaceutische Kengetallen. Beoogde besparing op statines onzeker. Pharmaceutisch Weekblad. 2009;144. Available at: http://www.sfk.nl/
Hess G, Sanders KN, Hill J, et al. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care. 2007;13 Suppl 3:S80–5. PubMed
Bestehorn K, Greiner W. Effects of the introduction of fixed prices for statins on lipid levels in Germany. J Publ Health. 2008;16:215–9. CrossRef
Phillips B, Roberts C, Rudolph AE, et al. Switching statins: the impact on patient outcomes. Br J Cardiol. 2007;14:280–5.
Colivicchi F, Tubaro M, Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol. 2010.
- Potential cardiovascular consequences of switching from atorvastatin to generic simvastatin in the Netherlands
J. W. Jukema
- Bohn Stafleu van Loghum